Ushiku, Japan

Oguri Tomei


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Oguri Tomei: Innovator in Carboxystyrene Derivatives

Introduction

Oguri Tomei is a notable inventor based in Ushiku, Japan. He has made significant contributions to the field of pharmaceuticals through his innovative work on carboxystyrene derivatives. His research has led to advancements in drug formulations that can potentially improve therapeutic outcomes.

Latest Patents

Oguri Tomei holds a patent for "Carboxystyrene derivatives and drugs containing them as effective." This invention provides novel carboxystyrene derivatives of a specific general formula. The patent also includes leukotriene antagonists and phospholipase inhibitors that utilize the carboxystyrene derivative or its pharmaceutically acceptable salt as an effective ingredient. This work highlights the potential of these compounds in medical applications.

Career Highlights

Tomei is associated with Mitsubishi Kasei Corporation, where he has been able to apply his expertise in chemistry and pharmaceuticals. His work has contributed to the company's reputation as a leader in innovative drug development. With a focus on creating effective pharmaceutical solutions, he has established himself as a key figure in his field.

Collaborations

Some of his notable coworkers include Yoshio Hayashi and Masaki Shinoda. Their collaborative efforts have further enhanced the research and development initiatives at Mitsubishi Kasei Corporation.

Conclusion

Oguri Tomei's contributions to the field of pharmaceuticals through his patent on carboxystyrene derivatives demonstrate his innovative spirit and commitment to advancing medical science. His work continues to inspire future research and development in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…